KR101490221B1 - 항박테리아 퀴놀린 유도체 - Google Patents

항박테리아 퀴놀린 유도체 Download PDF

Info

Publication number
KR101490221B1
KR101490221B1 KR1020097012572A KR20097012572A KR101490221B1 KR 101490221 B1 KR101490221 B1 KR 101490221B1 KR 1020097012572 A KR1020097012572 A KR 1020097012572A KR 20097012572 A KR20097012572 A KR 20097012572A KR 101490221 B1 KR101490221 B1 KR 101490221B1
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
compound
het
pyrimidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097012572A
Other languages
English (en)
Korean (ko)
Other versions
KR20090087071A (ko
Inventor
제롬 에밀 조르쥬 길레몽
마갈리 마들렌 시몬 모테
코엔라트 요제프 로데윅 마르셀 안드리스
아닐 코울
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20090087071A publication Critical patent/KR20090087071A/ko
Application granted granted Critical
Publication of KR101490221B1 publication Critical patent/KR101490221B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1020097012572A 2006-12-06 2007-12-04 항박테리아 퀴놀린 유도체 Expired - Fee Related KR101490221B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125521 2006-12-06
EP06125521.2 2006-12-06
PCT/EP2007/063315 WO2008068269A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
KR20090087071A KR20090087071A (ko) 2009-08-14
KR101490221B1 true KR101490221B1 (ko) 2015-02-05

Family

ID=37944337

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012572A Expired - Fee Related KR101490221B1 (ko) 2006-12-06 2007-12-04 항박테리아 퀴놀린 유도체

Country Status (29)

Country Link
US (1) US7998979B2 (enExample)
EP (1) EP2086941B1 (enExample)
JP (1) JP5356245B2 (enExample)
KR (1) KR101490221B1 (enExample)
CN (1) CN101541752B (enExample)
AR (1) AR064150A1 (enExample)
AT (1) ATE465994T1 (enExample)
AU (1) AU2007328889B2 (enExample)
BR (1) BRPI0720251B8 (enExample)
CA (1) CA2668520C (enExample)
CL (1) CL2007003516A1 (enExample)
CY (1) CY1110706T1 (enExample)
DE (1) DE602007006231D1 (enExample)
DK (1) DK2086941T3 (enExample)
ES (1) ES2344535T3 (enExample)
HR (1) HRP20100384T1 (enExample)
IL (1) IL199081A (enExample)
JO (1) JO2685B1 (enExample)
ME (1) ME01073B (enExample)
MX (1) MX2009005980A (enExample)
NO (1) NO341995B1 (enExample)
NZ (1) NZ576673A (enExample)
PL (1) PL2086941T3 (enExample)
PT (1) PT2086941E (enExample)
RS (1) RS51390B (enExample)
RU (1) RU2446159C2 (enExample)
SI (1) SI2086941T1 (enExample)
TW (1) TWI412364B (enExample)
WO (1) WO2008068269A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005070430A1 (en) 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
WO2005117875A1 (en) 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
KR20040055774A (ko) * 2001-07-31 2004-06-26 웨인 스테이트 유니버시티 퀴놀린 유도체 및 항종양제로서 그의 용도
WO2005070924A1 (en) 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
ES2306098T3 (es) * 2004-01-29 2008-11-01 Janssen Pharmaceutica Nv Derivados de quinolina para uso como inhibidores de micobacterias.
ME02935B (me) 2004-09-28 2018-04-20 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005070430A1 (en) 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
WO2005117875A1 (en) 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
HK1137428A1 (en) 2010-07-30
NO20092540L (no) 2009-09-07
DK2086941T3 (da) 2010-08-09
JP5356245B2 (ja) 2013-12-04
CN101541752A (zh) 2009-09-23
TW200845987A (en) 2008-12-01
AU2007328889B2 (en) 2012-12-06
BRPI0720251B1 (pt) 2020-10-06
ATE465994T1 (de) 2010-05-15
CA2668520A1 (en) 2008-06-12
PL2086941T3 (pl) 2010-10-29
HRP20100384T1 (hr) 2010-08-31
SI2086941T1 (sl) 2010-08-31
NZ576673A (en) 2011-09-30
AU2007328889A1 (en) 2008-06-12
DE602007006231D1 (de) 2010-06-10
ES2344535T3 (es) 2010-08-30
BRPI0720251A2 (pt) 2014-01-07
WO2008068269A1 (en) 2008-06-12
US7998979B2 (en) 2011-08-16
PT2086941E (pt) 2010-07-14
RU2009125525A (ru) 2011-01-20
CL2007003516A1 (es) 2008-07-11
EP2086941A1 (en) 2009-08-12
CN101541752B (zh) 2013-07-17
JP2010511670A (ja) 2010-04-15
US20100063061A1 (en) 2010-03-11
CY1110706T1 (el) 2015-06-10
TWI412364B (zh) 2013-10-21
NO341995B1 (no) 2018-03-12
EP2086941B1 (en) 2010-04-28
MX2009005980A (es) 2009-06-16
ME01073B (me) 2012-10-20
CA2668520C (en) 2016-01-26
AR064150A1 (es) 2009-03-18
RU2446159C2 (ru) 2012-03-27
RS51390B (sr) 2011-02-28
JO2685B1 (en) 2013-03-03
KR20090087071A (ko) 2009-08-14
IL199081A (en) 2013-08-29
BRPI0720251B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
KR101490222B1 (ko) 항균성 퀴놀린 유도체
KR101514992B1 (ko) 항균성 퀴놀린 유도체
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
KR101574642B1 (ko) 항균성 퀴놀린 유도체
KR101553600B1 (ko) 항균성 퀴놀린 유도체
JP5193858B2 (ja) 抗菌剤としてのキノリン誘導体
HK1137431B (en) Antibacterial quinoline derivatives
HK1137428B (en) Antibacterial quinoline derivatives
HK1137441B (en) Antibacterial quinoline derivatives
EA040841B1 (ru) Антибактериальные производные хинолина
HK1137433B (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20180103

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240131

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240131